Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance
{{output}}
Therapeutic resistance remains a major challenge in cancer treatment, driven by compensatory signaling and stress response pathways that sustain tumor survival. Topoisomerase IIβ-binding protein 1 (TopBP1), a multifunctional scaffold protein with nine BRCT do... ...
